Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has a beta value of 1.3 and has seen 10,930,967 shares traded in the recent trading session. The company, currently valued at $132.29 Million, closed the recent trade at $0.87 per share which meant it gained $0.11 on the day or 13.27% during that session. The ADMP stock price is -168.97% off its 52-week high price of $2.34 and 63.22% above the 52-week low of $0.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.38 Million shares traded. The 3-month trading volume is 19.82 Million shares.
The consensus among analysts is that Adamis Pharmaceuticals Corporation (ADMP) is a Hold stock at the moment, with a recommendation rating of 3. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 3 out of 3 have rated it as a Hold, with no one of them advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.06.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) trade information
Sporting 13.27% in the green today, the stock has traded in the green over the last five days, with the highest price hit on Tuesday, May 04 when the ADMP stock price touched $0.888 or saw a rise of 1.07%. Year-to-date, Adamis Pharmaceuticals Corporation shares have moved 81.1%, while the 5-day performance has seen it change 14.58%. Over the past 30 days, the shares of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) have changed -5.49%. Short interest in the company has seen 4.2 Million shares shorted with days to cover at 0.21.
Wall Street analysts have a consensus price target for the stock at $1.5, which means that the shares’ value could jump 72.41% from the levels at last check today. The projected low price target is $1.5 while the price target rests at a high of $1.5. In that case, then, we find that the latest price level in today’s session is +72.41% off the targeted high while a plunge would see the stock lose 72.41% from the levels at last check today.
Adamis Pharmaceuticals Corporation (ADMP) estimates and forecasts
Figures show that Adamis Pharmaceuticals Corporation shares have outperformed across the wider relevant industry. The company’s shares have gained +4.3% over the past 6 months, with this year growth rate of 52.94%, compared to 16.6% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 60% and 66.7% for the next quarter. Revenue growth from the last financial year stood is estimated to be -17.2%.
2 analysts offering their estimates for the company have set an average revenue estimate of $3.47 Million for the current quarter. 2 have an estimated revenue figure of $3.09 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $4.66 Million for this quarter, and analysts expect sales will grow by -25.6% for the current quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was +9% over the past 5 years. Earnings growth for 2021 is a modest -23.3%.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP)’s Major holders
Insiders own 0.56% of the company shares, while shares held by institutions stand at 3.88% with a share float percentage of 3.9%. Investors are also buoyed by the number of investors in a company, with Adamis Pharmaceuticals Corporation having a total of 42 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 2.06 Million shares worth more than $1Million. As of December 30, 2020, Vanguard Group, Inc. (The) held 1.39% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 1.33 Million shares as of December 30, 2020. The firm’s total holdings are worth over $646.91 Thousand and represent 0.9% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. As of December 30, 2020, the former fund manager holds about 0.74% shares in the company for having 1099333 shares of worth $533.29 Thousand while later fund manager owns 906.42 Thousand shares of worth $439.71 Thousand as of December 30, 2020, which makes it owner of about 0.61% of company’s outstanding stock.